N/A N=109 Non-Interventional Study Describing Direct Costs Related to Anti-coagulation Treatment
Atrial Fibrillation
Primary: CHA2-DS2-VASc Score at Baseline — 4.6; 4.3 Units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Early Phase 1 N=8 Suvorexant and Cocaine
Cocaine Use Disorder
Primary: Reinforcing Effects of Cocaine — 1.3; 5.0; 8.3; 0 Number of Cocaine Choices
Phase 2 N=30 Safety, Tolerability, and Efficacy of Doxorubicin and Pembrolizumab for Sarcoma
Soft Tissue Sarcoma, Adult · Soft Tissue Sarcoma, Child
Primary: Number of Participants With at Least One Severe or Life-Threatening Adverse Event — 1 Participants
Phase 4 N=25 Ketamine for Older Adults Pilot
Treatment Resistant Depression · Refractory Depression · Therapy-Resistant Depression
Primary: Remission From Depression — 6; 4 Participants
Phase 3 N=20 Treatment of Sunflower Syndrome With ZX008 (Fenfluramine Hydrochloride) in Children and Young Adults (Ages 4-25).
Photosensitive Epilepsy
Primary: % Change in Frequency of Handwaving Episodes — -66.2 % change in hand waving episodes — p=<0.001
Phase 3 N=309 Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation
Corticosteroid Refractory Acute Graft vs Host Disease
Primary: Overall Response Rate (ORR) at Day 28 — 62.3; 39.4 Percentage of participants — p=<.0001
N/A N=35 Wear Experience With Daily Contact Lenses Over a Long Day
Contact Lens
Primary: Subjective Overall Comfort as Assessed Using the Visual Analog Scale (VAS) — 93 units on a scale
N/A N=87 Fourth Trimester - A Web-based Tool for Postpartum Care to Address the Needs of Underserved Women
Pregnancy Related · Postpartum Sadness
Primary: Change From Baseline Resilience at 4 Weeks — 26.57; 28.29; 1.85 score on a scale — p=<.001
Phase 2 N=3 Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer
Metastatic Lung Non-Squamous Non-Small Cell Carcinoma · Recurrent Lung Non-Squamous Non-Small Cell Carcinoma · Stage IV Lung Non-Small Cell Cancer AJCC v7
Primary: Progression-free Survival (PFS) — 6.35; 14.3 months
Phase 2 N=46 Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic Dermatitis
Atopic Dermatitis
Primary: Fold-Change From Baseline in Atopic Dermatitis Biomarkers in Lesional and Non-lesional Skin at Week 12 — -5.896; -15.604; -0.729; -0.506 Fold change
Phase 2 N=80 An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients
Gastric Cancer · GastroEsophageal Cancer
Primary: Number of Patients With Treatment Emergent Adverse Events (TEAE) — 61; 19 Participants
Phase 2 N=96 Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies
Hematologic Malignancies · Acute Myeloid Leukemia · Acute Lymphoblastic Leukemia
Primary: Percentage of Participants With Cumulative Incidence of Grade II to IV aGvHD Through Day +100 Based on Investigator Assessment — 42.9; 44.4; 24.9 percentage of…
Phase 3 N=100 Efficacy and Safety Study of Glucosamine/Chondroitin Sulfate to Patients Treatment With Osteoarthrosis of the Knee
Osteoarthritis of the Knee
Primary: To Assess the Efficacy and Safety of the Association of Glucosamine Sulphate 500 mg/Chondroitin Sulphate 400 mg (Eurofarma) in the Treatment of Osteoarthritis, Compared…
N/A N=92 Improving Sleep Using Mentored Behavioral and Environmental Restructuring
Insomnia
Primary: Sleep Efficiency (SE) — 76.1 percentage of time in bed
Phase 4 N=13 Bowel Care and Cardiovascular Function After Spinal Cord Injury
Spinal Cord Injury
Primary: Blood Pressure Change During Bowel Care — 90.5; 80 mmHg